Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Clin Cardiol. 2024 May;47(5):e24268. doi: 10.1002/clc.24268.
Observational studies suggest that valvular surgery can reduce mortality in selected patients with infective endocarditis (IE). However, the benefit of this intervention according to frailty levels remains unclear. Our study aims to assess the effect of valvular surgery according to frailty status in this population.
We performed a retrospective study using the 2016-2019 National Inpatient Sample database. Adult patients with a primary diagnosis of IE were included. Frailty was assessed using the Hospital Frailty Risk Score. Inverse probability of treatment weighting (IPTW) was used to balance baseline differences between groups.
A total of 53,275 patients with IE were included, with 18.3% underwent valvular surgery. The median age was 52 (34-68) years, with 41% females. Overall, 42.7% had low risk of frailty, 53.1% intermediate risk, and 4.2% high risk. After IPTW adjustment, in-hospital mortality was similar both for the entire cohort between valvular and non-valvular surgery groups (3.7% vs. 4.1%, p = .483), and low (1% vs. 0.9%, p = .952) or moderate (5.4% vs. 6%, p = .548) risk of frailty. However, patients at high risk of frailty had significantly lower in-hospital mortality in the valvular surgery group (4.6% vs. 13.9%, p = .016). Renal replacement therapy was similar between groups across frailty status. In contrast, surgery was associated with increased use of mechanical circulatory support and pacemaker implantation.
Our findings suggest that there was no difference in survival between valve surgery and medical management in patients at low/intermediate frailty risk, but not for high-risk individuals.
观察性研究表明,在选择的感染性心内膜炎(IE)患者中,瓣膜手术可以降低死亡率。然而,根据虚弱程度,这种干预的益处尚不清楚。我们的研究旨在评估该人群中根据虚弱程度进行瓣膜手术的效果。
我们使用 2016-2019 年全国住院患者样本数据库进行了回顾性研究。纳入患有原发性 IE 的成年患者。使用医院衰弱风险评分评估虚弱程度。使用逆概率治疗加权(IPTW)来平衡组间基线差异。
共纳入 53275 例 IE 患者,其中 18.3%接受了瓣膜手术。中位年龄为 52 岁(34-68 岁),女性占 41%。总体而言,42.7%的患者衰弱风险低,53.1%的患者衰弱风险中等,4.2%的患者衰弱风险高。经过 IPTW 调整后,在整个队列中,瓣膜手术组和非瓣膜手术组的院内死亡率相似(3.7% vs. 4.1%,p=0.483),且衰弱风险低(1% vs. 0.9%,p=0.952)或中度(5.4% vs. 6%,p=0.548)。然而,在衰弱风险高的患者中,瓣膜手术组的院内死亡率显著降低(4.6% vs. 13.9%,p=0.016)。各组的肾脏替代治疗在各虚弱程度之间相似。相比之下,手术与机械循环支持和起搏器植入的使用增加相关。
我们的研究结果表明,在低/中度衰弱风险患者中,瓣膜手术与药物治疗之间的生存率无差异,但在高危患者中并非如此。